4,071 Shares in Zoetis Inc. (NYSE:ZTS) Purchased by Fiduciary Alliance LLC

Fiduciary Alliance LLC bought a new position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 4,071 shares of the company's stock, valued at approximately $663,000.

Several other hedge funds have also added to or reduced their stakes in the business. Cherry Creek Investment Advisors Inc. lifted its position in shares of Zoetis by 2.0% in the 3rd quarter. Cherry Creek Investment Advisors Inc. now owns 3,021 shares of the company's stock worth $590,000 after purchasing an additional 58 shares during the period. Grove Bank & Trust lifted its position in shares of Zoetis by 0.5% in the 3rd quarter. Grove Bank & Trust now owns 11,763 shares of the company's stock worth $2,298,000 after purchasing an additional 61 shares during the period. Hancock Whitney Corp lifted its position in shares of Zoetis by 0.3% in the 3rd quarter. Hancock Whitney Corp now owns 18,569 shares of the company's stock worth $3,628,000 after purchasing an additional 61 shares during the period. Strategy Asset Managers LLC lifted its position in shares of Zoetis by 3.5% in the 3rd quarter. Strategy Asset Managers LLC now owns 1,822 shares of the company's stock worth $356,000 after purchasing an additional 62 shares during the period. Finally, Edge Capital Group LLC lifted its position in shares of Zoetis by 3.7% in the 2nd quarter. Edge Capital Group LLC now owns 1,786 shares of the company's stock worth $310,000 after purchasing an additional 64 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Stock Down 1.2 %

ZTS stock traded down $2.01 during midday trading on Tuesday, reaching $164.31. 3,608,112 shares of the company's stock traded hands, compared to its average volume of 2,586,751. The company has a market cap of $74.13 billion, a price-to-earnings ratio of 30.89, a P/E/G ratio of 2.91 and a beta of 0.89. The firm's fifty day moving average price is $171.53 and its 200-day moving average price is $180.22. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.53.

Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The firm had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.29 billion. During the same quarter in the prior year, the business posted $1.36 EPS. The business's revenue was up 11.6% compared to the same quarter last year. As a group, sell-side analysts forecast that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, January 21st will be paid a $0.50 dividend. This is a positive change from Zoetis's previous quarterly dividend of $0.43. The ex-dividend date is Tuesday, January 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.22%. Zoetis's dividend payout ratio is presently 37.59%.

Analyst Ratings Changes

Several research firms have recently weighed in on ZTS. Leerink Partnrs upgraded shares of Zoetis to a "strong-buy" rating in a research note on Monday, December 2nd. UBS Group began coverage on shares of Zoetis in a research note on Monday, December 9th. They issued a "neutral" rating and a $196.00 price objective for the company. JPMorgan Chase & Co. lifted their price objective on shares of Zoetis from $225.00 to $230.00 and gave the company an "overweight" rating in a research note on Friday, October 11th. Leerink Partners began coverage on shares of Zoetis in a research note on Monday, December 2nd. They issued an "outperform" rating and a $215.00 price objective for the company. Finally, Stifel Nicolaus lowered their price objective on shares of Zoetis from $210.00 to $180.00 and set a "buy" rating for the company in a research note on Tuesday, January 7th. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of "Buy" and an average price target of $211.89.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.